Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus

Alvaro Gomez¹,², Fawz Hani Butrus¹,², Petter Johansson¹,², Emil Åkerström¹,², Sofia Soukka¹,², Sharzad Emamikia¹,², Yvonne Enman¹,², Susanne Pettersson¹,²,³ and Ioannis Parodis¹,²

Abstract

Objectives. Associations between BMI and health-related quality of life (HRQoL) in SLE have been implied, but data are scarce. We determined the impact of overweight and obesity on HRQoL in a large SLE population.

Methods. We pooled cross-sectional baseline data from the BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) trials (N = 1684). HRQoL was evaluated using the 36-item Short Form Health Survey (SF-36), Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale and the European Quality of Life 5-dimension questionnaire (EQ-5D). Comparisons between BMI groups were conducted using the Mann–Whitney U test and adjustments using linear regression. Clinical relevance was determined by minimal clinically important differences (MCIDs).

Results. In total, 43.2% of the patients had BMI above normal and 17.4% were obese. Overweight and obese patients reported worse SF-36 physical component summary (PCS), physical functioning, role physical, bodily pain and FACIT-Fatigue scores than normal weight patients. Divergences were greater than corresponding MCIDs and more prominent with increasing BMI. Despite no clinically important difference in SF-36 mental component summary scores across BMI categories, patients experienced progressively diminished vitality and social functioning with increasing BMI. In linear regression analysis, BMI above normal and obesity were associated with worse PCS (standardized coefficient $\beta = -0.10$, $P < 0.001$ and $\beta = -0.17$, $P < 0.001$, respectively), FACIT-Fatigue ($\beta = -0.11$, $P < 0.001$ and $\beta = -0.16$, $P < 0.001$) and EQ-5D ($\beta = -0.08$, $P = 0.001$ and $\beta = -0.12$, $P < 0.001$) scores, independently of demographic and disease-related factors. The impact of BMI on the PCS and FACIT-Fatigue was more pronounced than that of SLE activity.

Conclusion. Patients with SLE and BMI above normal experienced clinically important HRQoL diminutions in physical aspects, fatigue and social functioning. A survey of potential causality underlying this association is warranted.

Key words: SLE, health-related quality of life, obesity, patient-reported outcomes
Introduction

SLE is a chronic multisystem autoimmune disease that most commonly affects women of childbearing age. Despite considerable advances on improving life expectancy and preventing organ damage accrual over the past decades [1], patients with SLE still experience a substantially impaired health-related quality of life (HRQoL) compared with the general population, and constitutional symptoms such as fatigue remain frequent complaints [2–4].

Factors contributing to HRQoL diminutions in patients with SLE include fatigue, pain, depression and increased BMI [2, 5–7]. Obesity is associated with poor functional capacity, high concentrations of inflammatory markers and high disease activity [8–10]. In juvenile-onset SLE, obesity has detrimental effects on overall HRQoL [6]. In adult SLE patients, higher BMI is associated with an impaired physical HRQoL [5, 6], while the effect regarding mental aspects remains controversial, with inconsistent reports from different cohorts [5, 6, 9]. Overall, data are scarce and conflicting and the clinical significance of the associations between BMI and HRQoL has not been thoroughly investigated.

In the present study, the aim was to determine the impact of overweight and obesity on physical and mental HRQoL aspects in the large SLE populations of the BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) clinical trials.

Methods

Study design and population

This is a post hoc analysis of prospectively collected data from two phase 3 randomized clinical trials of belimumab in SLE, i.e. the BLISS-52 [11] and BLISS-76 [12] trials. The study design was cross-sectional. We utilized pooled baseline data from the two trials (n = 1684), i.e. data collected prior to the intended trial intervention.

The BLISS-52 trial comprised 865 adult seropositive (ANA titre ≥1:80 and/or anti-dsDNA antibody ≥30 IU/ml) patients with active SLE, defined as a Safety of Estrogen in Lupus National Assessment–SLEDAI (SELENA-SLEDAI) [13] score ≥6 at enrolment despite standard of care therapy, the latter comprising fixed doses of corticosteroids, NSAIDs, antimalarial agents or immunosuppressants for at least 30 days before the first study dose. Organ damage was assessed using the SLICC/ACR Damage Index (SDI) [14]. The BLISS-76 trial included 819 patients with SLE and had a similar design to that of the BLISS-52 trial, but a longer follow-up until week 76.

The similarity in the design allowed us to analyse pooled data from the two trials. After exclusion of three patients with no available BMI data, the total number of patients qualifying for analysis was 1681. However, since BLISS-52 was primarily conducted in Latin America, Asia Pacific and Eastern Europe while BLISS-76 was primarily conducted in North America and Europe, we also performed separate analyses of data from the BLISS-52 and BLISS-76 trials. Data were made available by GlaxoSmithKline (Uxbridge, UK) through the Clinical Study Data Request Consortium.

The study was conducted in compliance with the ethical principles of the Declaration of Helsinki. Written informed consent was obtained from all study participants prior to enrolment in the BLISSS programmes. Ethical permission for the present investigation was obtained by the Swedish ethical review authority (ref. 2019-05498).

Measurements of HRQoL

SLE patients’ perception of HRQoL was determined using generic instruments, i.e. the Medical Outcomes Study (MOS) 36-item Short Form Health Survey (SF-36) [15], the three-level European Quality of Life 5-dimension (EQ-5D) health questionnaire [16] and the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale [17]. The SF-36 questionnaire consists of 36 questions, grouped in eight subscales, i.e. physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), social functioning (SF), vitality (VT), role emotional (RE) and mental health (MH). The responses to the SF-36 were scored with the SF-36v2 manual [18], yielding subscale scores from 0 to 100. Next, the SF-36 subscales were computed according to a three-step procedure, including Z-score transformation and weighting based on the general US population, to generate two summary measures, the physical component summary (PCS) and the mental component summary (MCS). Although all subscales are weighted in the derivation of PCS and MCS, PF, RP, BP and GH are referred to as the physical aspects and SF, VT, RE and MH as the mental aspects of the SF-36. In terms of interpretation, higher scores on SF-36 subscales and component summaries represent a better HRQoL.

The FACIT-Fatigue scale is a generic 13-item questionnaire that assesses the impact of fatigue over the preceding 7 days. The scores generated have a span from 0 to 52, with higher scores representing greater fatigue.

The three-level EQ-5D health questionnaire consists of two distinct indices, i.e. a visual analogue scale (VAS) measuring patients’ health perception from 0 (worst health perception) to 100 (best health perception) and a questionnaire consisting of five questions addressing self-care, mobility, daily activity, pain/discomfort and anxiety/depression. Patients’ responses to these five questions are next summarized into a utility index score. In the present study, EQ-5D utility index scores were calculated based on the valuation of EQ-5D health states from a general US population sample [19]. In terms of interpretation, higher utility index scores represent a better HRQoL.

BMI and HRQoL

The patients were stratified into four groups based on their BMI according to cut-off values established by the
World Health Organization (WHO): underweight (BMI <18.5 kg/m²), normal weight (18.5 ≤ BMI < 25 kg/m²), overweight (25 ≤ BMI <30 kg/m²) and obesity (BMI ≥30 kg/m²) [20]. Further, we divided the obesity group into three subgroups: type I obesity (30 ≤ BMI <35 kg/m²), type II obesity (35 ≤ BMI <40 kg/m²) and type III obesity (BMI ≥40 kg/m²). In certain analyses, we grouped overweight and obese individuals into a subset herein termed ‘BMI above normal’ patients.

Next we determined minimal clinically important differences (MCIDs) for scores in the different HRQoL instruments, based on previously reported cut-offs. In cases of varying thresholds in the literature, the most stringent one was used. Thus the MCID for SF-36 PCS and MCS scores was defined as ≥2.5, while the corresponding MCID for SF-36 subscale scores was defined as ≥5.0 [21]. The MCID for FACIT-Fatigue scores was set to ≥4 [22, 23]. For the EQ-SD VAS, the MCID was defined as ≥10 [24] and for the EQ-5D utility index score it was set to ≥0.082 [25].

Statistical analysis
Data are presented as number (percentage) or mean (s.d.). For comparisons between BMI groups, the non-parametric Mann–Whitney U test was used. The Pearson’s χ² test was used to investigate contingent associations between binomial variables. Finally, linear regression analysis was used to evaluate associations of demographic and clinical factors with different HRQoL aspects. Multiple linear regression models were created for assessment of independence and confounding potentiality. P-values < 0.05 were considered statistically significant. Statistical analyses were performed using the SPSS software version 25 (IBM, Armonk, NY, USA). GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA) was used for the construction of graphs.

Results
Patient characteristics
Table 1 summarizes demographic and SLE disease characteristics across BMI groups. Supplementary Table S1, available at Rheumatology online, shows the corresponding data for the BMI above normal group and the different obesity subgroups.

A total of 727 of 1681 patients (43.2%) had a BMI over the normal range, while 293 participants (17.4%) were obese. The prevalence of BMI above normal and obesity were highest among Black/African American patients (63.7% and 30.1%, respectively), with the corresponding proportions among White/Caucasian being 48.9% and 22.5%, among Native American 42.0% and 13.4% and among Asian patients 22.1% and 4.0%, respectively.

There was no difference in SELENA-SLEDAI scores across different BMI groups. However, overweight [0.82 (s.d. 1.30), P = 0.006] and obese patients [1.19 (s.d. 1.54), P < 0.001] had higher SDI scores compared with SLE patients of normal weight [0.63 (s.d. 1.07)].

The frequency of patients receiving antimalarial agents was lower within the overweight group (61.1%) compared with the normal weight group (67.8%; P = 0.015). In contrast, the proportion of patients receiving immunosuppressive agents was higher within the obesity group (54.9%) compared with the normal weight group (46.3%; P = 0.011). Notably, obese patients were on lower daily prednisone equivalent doses [9.2 mg/day (s.d. 8.0)] than patients with normal BMI [11.3 mg/day (s.d. 8.5), P < 0.001; Table 1].

MOS SF-36
Overweight and obese patients reported lower PCS, PF, RP and BP scores compared with normal weight patients; the differences were greater than the corresponding MCIDs and more prominent with increasing BMI (Fig. 1). The obese group had lower GH scores [36.5 (s.d. 18.6)] compared with normal weight patients [42.4 (s.d. 18.9), P < 0.001; Supplementary Table S2, available at Rheumatology online] and the differences were greater than the MCIDs in the type 2 and 3 but not the type 1 obesity subgroups. All three obesity subgroups reported worse PCS, PF, BP and GH scores compared with the overweight group (Fig. 1). In the BLISS-52 trial, we observed clinically important differences between patients with BMI above normal and normal weight patients in PF and RP and between obese and normal weight patients in PCS, PF, RP and BP (Supplementary Table S3, available at Rheumatology online). In the BLISS-76 trial, patients with BMI above normal and obese patients experienced worse PCS, PF, RP and BP than normal weight patients, with the differences being greater than the corresponding MCIDs (Supplementary Table S4, available at Rheumatology online).

When mental HRQoL was analysed, overweight patients had lower MCS scores [39.8 (s.d. 11.8)] than normal weight subjects [41.5 (s.d. 11.2), P = 0.029], but the difference was not clinically important (<MCID), whereas obese patients did not show differences compared with the other groups (Fig. 1). However, we found progressively reduced VT and SF scores with increasing BMI, with all obesity subgroups displaying clinically meaningful differences (>MCID) compared with the normal weight group. MH scores did not differ across the BMI groups (Fig. 1). In analysis stratified by trial, the difference in MCS and MH scores exceeded the MCID in the BLISS-52 trial (Supplementary Table S3, available at Rheumatology online) but not in the BLISS-76 trial (Supplementary Table S4, available at Rheumatology online) in the comparison between obese and normal weight patients, while VT and SF scores showed greater differences than the corresponding MCID in both trials.

No differences were seen in SF-36 component summary or subscale scores between underweight and normal weight SLE patients (Supplementary Table S5, available at Rheumatology online).
### Table 1 Demographic and clinical characteristics of patients

| Characteristics                        | Normal weight (N = 874) | Underweight (N = 80) | Overweight (N = 434) | Obese (N = 233) | P-value | P-value | P-value |
|---------------------------------------|-------------------------|----------------------|----------------------|----------------|---------|---------|---------|
| Demographics                          |                         |                      |                      |                |         |         |         |
| Age, years, mean (s.d.)               | 35.4 (10.9)             | 30.0 (9.3)           | <0.001               | 40.2 (11.5)    | <0.001  | 43.4 (10.7) | <0.001  |
| Sex (female), n (%)                   | 831 (95.1)              | 78 (97.5)            | 0.328                | 397 (91.5)     | 0.010   | 276 (94.2) | 0.554   |
| Ethnic origin, n (%)                  |                         |                      |                      |                |         |         |         |
| Asian                                 | 240 (27.5)              | 35 (43.8)            | 0.002                | 64 (14.7)      | <0.001  | 14 (4.8) | <0.001  |
| Black/African American                 | 47 (5.4)                | 6 (7.5)              | 0.428                | 49 (11.3)      | <0.001  | 44 (15.0) | <0.001  |
| Indigenous American<sup>a</sup>        | 206 (23.6)              | 11 (13.8)            | 0.045                | 107 (24.7)     | 0.665   | 50 (17.1) | 0.020   |
| White/Caucasian                       | 378 (43.2)              | 28 (35.0)            | 0.153                | 210 (48.4)     | 0.079   | 179 (61.1) | <0.001  |
| Clinical characteristics and concomitant treatments |          |                      |                      |                |         |         |         |
| SELENA-SLEDAI score, mean (s.d.)      | 9.6 (3.6)               | 10.4 (4.3)           | 0.174                | 9.8 (3.8)      | 0.529   | 9.7 (3.4) | 0.972   |
| SLE duration, years, mean (s.d.)      | 6.3 (6.3)               | 4.9 (5.5)            | 0.056                | 6.4 (6.5)      | 0.957   | 7.1 (6.6) | 0.055   |
| SDI score, mean (s.d.)                | 0.63 (1.07)             | 0.61 (1.0)           | 0.880                | 0.82 (1.30)    | 0.006   | 1.19 (1.54) | <0.001  |
| Glucocorticoid use, n (%)             | 784 (89.7)              | 74 (92.5)            | 0.426                | 368 (84.8)     | 0.002   | 229 (77)  | <0.001  |
| Prednisone dose, mg/day, mean (s.d.)  | 11.3 (8.5)              | 11.2 (8.4)           | 0.785                | 10.8 (9.3)     | 0.101   | 9.2 (8.0) | <0.001  |
| IS use<sup>b</sup>, n (%)             | 405 (46.3)              | 33 (41.3)            | 0.382                | 215 (49.5)     | 0.275   | 161 (54.9) | 0.011   |
| Azathioprine                          | 204 (23.3)              | 13 (16.3)            | 0.148                | 100 (23.0)     | 0.904   | 72 (24.6) | 0.667   |
| Methotrexate                          | 113 (12.9)              | 9 (11.3)             | 0.667                | 53 (12.2)      | 0.714   | 56 (19.1) | 0.009   |
| Mycophenolic acid                     | 87 (10.0)               | 10 (12.5)            | 0.471                | 58 (13.4)      | 0.064   | 32 (10.9) | 0.636   |
| AMA use, n (%)                        | 593 (67.8)              | 57 (71.3)            | 0.532                | 265 (61.1)     | 0.015   | 181 (61.8) | 0.057   |

P-values are derived from Pearson’s $r^2$ or Mann–Whitney U tests; the normal weight group was the reference comparator.

<sup>a</sup>Alaska Native or American Indian from North, South or Central America. <sup>b</sup>Excluding antimalarial agents. AMA: antimalarial agents; IS: immunosuppressants.

### FACIT-Fatigue

All groups of BMI above normal reported significantly worse FACIT-Fatigue scores compared with the normal weight group [32.1 (s.d. 11.5)] and displayed a gradual impairment with increasing BMI (Fig. 1). The differences were greater than the MCID for all obesity subgroups (type 1, 26.8 (s.d. 11.3); type 2, 24.6 (s.d. 13.6); type 3, 23.7 (s.d. 11.3), $P < 0.001$ for all), but not for the overweight group [29.0 (s.d. 12.1), $P < 0.001$]. Moreover, the differences were greater than the MCID for patients with BMI above normal and obese patients in the pooled dataset (Supplementary Table S2, available at Rheumatology online) and the BLISS-76 trial (Supplementary Table S4, available at Rheumatology online), but not in the BLISS-S2 trial (Supplementary Table S3, available at Rheumatology online).

We found no difference in FACIT-Fatigue scores between underweight and normal weight individuals (Supplementary Table S5, available at Rheumatology online).

### EQ-5D

Overweight and obese patients had worse EQ-5D VAS and utility index scores compared with normal weight subjects. The type 3 obesity subgroup reported worse EQ-5D utility index scores [0.65 (s.d. 0.19)] compared with the overweight group [0.72 (s.d. 0.19), $P = 0.006$]. The corresponding differences in the type 1 and 2 obesity subgroups were not statistically significant. None of the differences in the EQ-5D VAS or utility index scores between BMI groups were greater than the corresponding MCIDs (Fig. 1). Comparisons between patients with a BMI above normal and normal weight patients as well as between obese and normal weight patients are presented in Supplementary Table S2 for the pooled dataset, Supplementary Table S3 for the BLISS-S2 trial and Supplementary Table S4 for the BLISS-76 trial, available at Rheumatology online.

No difference was noted in the EQ-5D VAS or utility index scores between underweight and normal weight subjects (Supplementary Table S5, available at Rheumatology online).

### Linear regression analysis

We next assessed independence and confounding potentiality using multiple linear regression analysis. Based on reports from previous literature, selected covariates included age, sex, ethnicity, SELENA-SLEDAI score, SLE disease duration, SDI score, prednisone (or equivalent) dose and use of antimalarial or immunosuppressive agents [2, 5, 6, 26, 27].

First, we investigated associations between BMI and HRQoL using BMI as a continuous variable in the multivariable models (Fig. 2A–5A; Supplementary Fig. S1A, available at Rheumatology online; Supplementary Table S6, available at Rheumatology online). Higher BMI was independently associated with more severely impaired...
The physical aspects of HRQoL, i.e. lower PCS (standardized coefficient $\beta = -0.20$, $P < 0.001$), PF ($\beta = -0.23$, $P < 0.001$), RP ($\beta = -0.12$, $P < 0.001$), BP ($\beta = -0.12$, $P < 0.001$) and GH ($\beta = -0.13$, $P < 0.001$) scores (Supplementary Table S6, available at Rheumatology online). In contrast, no association was found between BMI and SF-36 MCS scores ($\beta = -0.04$, $P = 0.264$; Fig. 4A), but we found a negative impact of BMI on VT ($\beta = -0.16$, $P < 0.001$; Fig. 5A) and SF ($\beta = -0.11$, $P = 0.001$; Fig. 4A).

Next we created separate models for the BMI above normal group and the obesity group, with the normal weight group as the reference comparator in both cases (Fig. 2B and C–Fig. 5B and C; Supplementary Fig. S1B–C, available at Rheumatology online; Supplementary Table S7, available at Rheumatology online; Supplementary Table S8, available at Rheumatology online).
Obesity was independently associated with lower scores in all components related to physical HRQoL, whereas BMI above normal was negatively associated with PCS as well as all physical SF-36 aspects except GH (Figs 2 and 3).

The forest plots illustrate results from multiple linear regression models. (A) BMI was analysed as a continuous variable. Separate models for the (B) BMI above normal and (C) obesity groups were created, with the normal weight group as the reference comparator in both cases. The dark blue circles represent the unstandardized coefficients and the whiskers represent the 95% CIs. The red diamonds represent the standardized coefficients. Asterisks indicate statistically significant associations. Level of significance: *P < 0.05, **P < 0.01, ***P < 0.001. AMA: antimalarial agents.

Table S8, available at *Rheumatology* online. Obesity was independently associated with lower scores in all components related to physical HRQoL, whereas BMI above normal was negatively associated with PCS as well as all physical SF-36 aspects except GH (Figs 2 and 3). Notably, obesity was the covariate showing the most

---

**Fig. 2** Associations of BMI with SF-36 PCS and PF

| Baseline variable | SF-36 PCS (Negative impact) | SF-36 PCS (Positive impact) | SF-36 Physical functioning (Negative impact) | SF-36 Physical functioning (Positive impact) |
|-------------------|-----------------------------|-----------------------------|---------------------------------------------|---------------------------------------------|
| Age               |                             |                             |                                             |                                             |
| Sex               |                             |                             |                                             |                                             |
| Race              |                             |                             |                                             |                                             |
| SELENA-SLEDAI score |                             |                             |                                             |                                             |
| SDI score         |                             |                             |                                             |                                             |
| SLE disease duration |                             |                             |                                             |                                             |
| Prednisone eq. dose |                             |                             |                                             |                                             |
| IS use            |                             |                             |                                             |                                             |
| AMA use           |                             |                             |                                             |                                             |
| BMI above normal  |                             |                             |                                             |                                             |
| Obesity           |                             |                             |                                             |                                             |

---

**Table S8**, available at *Rheumatology* online. Obesity was independently associated with lower scores in all components related to physical HRQoL, whereas BMI above normal was negatively associated with PCS as well as all physical SF-36 aspects except GH (Figs 2 and 3). Notably, obesity was the covariate showing the most
pronounced associations with HRQoL diminutions in physical aspects, yielding greater absolute values of $\beta$ coefficients compared with age, SELENA-SLEDAI score, SDI score and disease duration. We found no association between obesity and MCS scores ($\beta = -0.04$, $P = 0.182$; Fig. 4; Supplementary Table S8, available at

The forest plots illustrate results from multiple linear regression models. (A) BMI was analysed as a continuous variable. Separate models for the (B) BMI above normal and (C) obesity groups were created, with the normal weight group as the reference comparator in both cases. The dark blue circles represent the unstandardized coefficients and the whiskers represent the 95% CIs. The red diamonds represent the standardized coefficients. Asterisks indicate statistically significant associations. Level of significance: *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$. IS: immunosuppressants; AMA: antimalarial agents.

Fig. 3 Associations of BMI with SF-36 RP and BP
BMI above normal (β = 0.09, P = 0.001 and β = -0.16, P < 0.001, respectively; Fig. 5) and SF (β = -0.09, P < 0.001 and β = -0.10, P = 0.001, respectively; Fig. 4).
Likewise, there was an association between diminished FACIT-Fatigue scores and high BMI, independent of SLE disease duration and prednisone equivalent dose positively impacting on FACIT-Fatigue scores and female sex, SELENA-SLEDAI score and SDI score negatively impacting on FACIT-Fatigue scores (Fig. 5). Furthermore, higher BMI was consistently associated with lower EQ-5D utility index scores in all models.

The forest plots illustrate results from multiple linear regression models. (A) BMI was analysed as a continuous variable. Separate models for the (B) BMI above normal and (C) obesity groups were created, with the normal weight group as the reference comparator in both cases. The dark blue circles represent the unstandardized coefficients and the whiskers represent the 95% CIs. The red diamonds represent the standardized coefficients. Asterisks indicate statistically significant associations. Level of significance: *P < 0.05, **P < 0.01, ***P < 0.001. IS: immunosuppressants; AMA: antimalarial agents.
Discussion

In the present post hoc analysis of the BLISS-52 and BLISS-76 trials, we demonstrated that overweight and obese patients with SLE experience clinically important impairments of HRQoL, especially with regard to physical aspects and fatigue. The observed associations were independent of age, sex, ethnic origin, disease duration, disease activity, organ damage accrual and current immunosuppressive treatment. Interestingly, we found that HRQoL diminutions were more prominent with increasing BMI with regard to physical domains, social functioning and fatigue.

The physical aspects of HRQoL showed the most prominent diminutions in patients with BMI above normal. These diminutions were clinically important regarding all outcomes in the obesity subgroups and all except SF-36 GH in overweight patients. Moreover, study participants with a gradually higher BMI experienced a gradually worse HRQoL in all physical SF-36 items. Importantly, these associations were independent of demographic and disease-related factors in linear regression analysis. Our findings are in conformity with previous studies of adult [5, 6] and juvenile [28] SLE populations, which, irrespective of the tool used for the HRQoL evaluation, reported poor physical performance in obese patients.

With regard to mental aspects of HRQoL, vitality and social functioning were substantially impaired in patients with BMI above normal. This association was more prominent with increasing BMI, including increasing degree of obesity. Again, it is worth noting that the observed associations were independent of the impact of disease activity, organ damage and current immunosuppressive treatment. Overweight patients reported poorer SF-36 MCS and RE compared with normal weight individuals, but these differences did not reach the cut-off of clinical importance and were absent in the comparison between obese and normal weight individuals. The lower numbers of patients in the groups of obesity-level BMI may constitute a possible explanation. Nonetheless, the divergent findings within mental aspects of HRQoL are in line with previous observations both in the general [29–31] and SLE [5, 6, 9] populations. However, the impact of BMI on fatigue was independent of comitant drug use, and even more prominent. These findings have to be interpreted with caution since the degree of SLE activity in this study was limited by the inclusion and exclusion criteria of the BLISS trials, in particular SELENA-SLEDAI scores ≥6 and no severe active renal or neuropsychiatric SLE. Nonetheless, the consistency of this association is of particular importance in light of fatigue being the most frequent complaint in patients with SLE, reported by up to 92% of patients in different cohorts [3, 34] and up to 23% of patients in remission [35], pointing to the need for exploration of the underlying reasons at a biological level.

One could argue that disease activity may constitute a link between BMI and fatigue, with overweight maintaining an inflammatory state [10], subsequently leading to fatigue. In the present study, however, we found no difference in the degree of SLE disease activity across the different BMI categories. Moreover, the literature has been conflicting regarding the relationship between disease activity and fatigue, with some studies reporting
Impact of BMI on SLE patients’ HRQoL

detrimental effects [5, 8, 29] and others showing no association [2, 36], even when the same tools for measuring disease activity were used. Herein, the impact of high BMI, in particular obesity, was more pronounced than the impact of disease activity on SF-36 VT and FACIT-Fatigue scores in multivariable regression models. Although the potential bias imposed by the selected SLE population of the BLISS trials has to be reckoned with during interpretation, our findings highlight the importance of including factors such as suboptimal weight in the clinical evaluation for the management of fatigued SLE patients. Indeed, fatigue is acknowledged as one of the most important components of the global SLE burden, which has important implications with regard to socio-economic facets [4]. Results from our study advocate for multidimensional strategies including non-pharmacological approaches, such as weight control, along with pharmacological interventions that have proven efficacy in reducing fatigue [22, 26, 37], towards optimization of patient care and use of societal resources.

Our results were interpreted in the context of previously determined thresholds for clinically important differences, validated for SLE populations [38–40]. The use of validated MCID allows clinicians, patients, researchers and policymakers to perform meaningful evaluations of the data, especially when interpretation of the numerical scales of different tools is not intuitive. Furthermore, defining MCID is particularly important when large patient samples are analysed, such as the one in the present post hoc analysis, since small and clinically futile numerical differences may reach the level of statistical significance [41, 42]. MCID utilized in the present study have been used to assess change over time in previous literature, i.e. improvement or worsening, whereas the comparisons herein were cross-sectional. For this reason, we chose to set the MCID to the highest thresholds previously reported. This stringent approach may underestimate some differences, such as the ones observed in the SF-36 MCS, EQ-5D utility index and EQ-5D VAS scores, but ensures the clinical relevance of our findings.

The post hoc nature of the present study was a limitation. The BLISS trials were not designed to evaluate patients’ HRQoL, and can be underpowered for detecting differences in certain indices. Moreover, our cross-sectional study was not designed to address the potential causal relationship between body weight and HRQoL. It is important to note that data collected within the frame of the BLISS-52 and BLISS-76 trials may differ from what is encountered in daily clinical practice, even if our investigation was based on baseline data only, i.e. prior to the trial intervention. This selection bias introduced by trial design may limit the generalizability of our findings. For instance, patients were strictly selected to have active SLE, defined as a SELENA-SLEDAI score ≥6, and a stable treatment regimen with a prednisone equivalent dose between 0 and 40 mg/day, antimalarial agents, NSAIDs or conventional immunosuppressants for a period of at least 30 days prior to baseline. Finally, patients with severe active lupus nephritis and central nervous system manifestations were excluded from the BLISS programmes. The potential impact of body weight remains to be addressed in these subsets of SLE patients, especially since the mental compartment of HRQoL is expected to be particularly affected in the latter group.

 Nonetheless, the large study population and the homogeneous data collection in the BLISS-52 and BLISS-76 trials allowed us to adjust for multiple factors known to impact SLE patients’ HRQoL and factors with confounding potentiality. To our knowledge, this is one of the largest analyses to date of SLE patients’ BMI in relation to HRQoL.

Conclusion

In the present analysis of 1681 patients with SLE, overweight and obesity were highly associated with clinically important HRQoL diminutions. High BMI was found to particularly impact physical HRQoL aspects, as well as fatigue and social functioning among mental aspects. The observed associations were independent of other factors, including disease activity, organ damage, and current treatment. Notably, the impact of BMI on physical aspects of HRQoL and fatigue was more pronounced than that of SLE disease activity, disease duration and organ damage. Longitudinal investigation to address causality is warranted. As a future perspective, results from such surveys could be a prelude to the implementation of weight control strategies as a complementary intervention to current pharmacological management of lupus patients.

Acknowledgements

The authors would like to thank GlaxoSmithKline (Uxbridge, UK) for sharing the data from the BLISS-52 (NCT00424476) and BLISS-76 (NCT00410384) trials with the Clinical Study Data Request Consortium, as well as all participating patients. Data will be made available by the corresponding author upon reasonable request. A.G., F.H.B. and I.P. were responsible for study conception. A.G., EÅ., Y.E. and I.P. were responsible for study coordination. A.G., F.H.B., P.J., S.S., S.E. and I.P. were responsible for data processing and statistics. A.G., F.H.B. and I.P. drafted the manuscript. A.G., Y.E., S.P. and I.P. were responsible for interpretation of the results. All authors read and critically revised the manuscript for intellectual content, approved its final version prior to submission and agree to be accountable for all aspects of the work.

Funding: This work was supported by the GlaxoSmithKline Investigator-Sponsored Studies programme and grants from the Swedish Rheumatism Association (R-932236), Professor Nanna Svartz Foundation (2019-00290), Ulla and Roland Gustafsson

https://academic.oup.com/rheumatology
Disclosure statement: The authors have declared no conflicts of interest.

Supplementary data
Supplementary data are available at Rheumatology online.

References
1. Tselios K, Gladman DD, Sheane BJ, Su J, Urowitz M. All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971–2013). Ann Rheum Dis 2019;78:802–6.
2. Azizoddin DR, Gandhi N, Weinberg S et al. Fatigue in systemic lupus: the role of disease activity and its correlates. Lupus 2019;28:163–73.
3. Pettersson S, Lövgren M, Eriksson LE et al. An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life. Scand J Rheumatol 2012;41:383–90.
4. Campbell R Jr, Cooper GS, Gilkeson GS. Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: mortality risk and quality of life early in the course of disease. Arthritis Rheum 2008;59:458–64.
5. Zhu LW, Zhang T, Pan HF, Li XP, Ye DQ. BMI, disease activity, and health-related quality-of-life in systemic lupus erythematosus. Clin Rheumatol 2010;29:1413–7.
6. Tamayo T, Fischer-Betz R, Beer S, Winkler-Rohlfing B, Schneider M. Factors influencing the health related quality of life in patients with systemic lupus erythematosus: long-term results (2001–2005) of patients in the German Lupus Erythematosus Self-Help Organization (LULA Study). Lupus 2010;19:1606–13.
7. Calderon J, Flores P, Aguirre JM et al. Impact of cognitive impairment, depression, disease activity, and disease damage on quality of life in women with systemic lupus erythematosus. Scand J Rheumatol 2017;46:273–80.
8. Chaigne B, Chizzolini C, Permeur T et al. Impact of disease activity on health-related quality of life in systemic lupus erythematosus—a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS). BMC Immunol 2017;18:17.
9. Rizk A, Ghelta TA, Nassef S, Abdallah A. The impact of obesity in systemic lupus erythematosus on disease parameters, quality of life, functional capacity and the risk of atherosclerosis. Int J Rheum Dis 2012;15:261–7.
10. Oeser A, Chung CP, Asanuma Y, Avalos I, Stein CM. Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum 2005;52:3651–9.
11. Navarra SV, Guzmán RM, Gallacher AE et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721–31.
12. Furie R, Petri M, Zamani O et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918–30.
13. Petri M, Kim MY, Kalunian KC et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550–8.
14. Gladman D, Ginzler E, Goldsmith C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363–9.
15. Ware J, Sherbourne C. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.
16. EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199–208.
17. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 2003;1:79.
18. Ware J. SF-36 health survey update. Spine 2000;25:3130–9.
19. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005;43:203–20.
20. World Health Organization. Obesity: preventing and managing the global epidemic. Geneva: World Health Organization, 2000.
21. Strand V, Crawford B. Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. Exp Rev Pharmacoecon Outcomes Res 2005;5:317–26.
22. Strand V, Levy RA, Cervera R et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis 2014;73:838–44.
23. Pettersson S, Lundberg IE, Liang MH, Pouchot J, Henriksson EW. Determination of the minimal clinically important difference for seven measures of fatigue in Swedish patients with systemic lupus erythematosus. Scand J Rheumatol 2015;44:215–20.
24. Bangert E, Wakani L, Merchant M, Strand V, Touma Z. Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies. Patient Relat Outcome Meas 2019;10:1–7.
25. Coretti S, Ruggeri M, McNamara P. The minimum clinically important difference for EQ-5D index: a critical review. Expert Rev Pharmacoecon Outcomes Res 2014;14:221–33.
26. Parodi I, Lopez Benavides AH, Zickert A et al. The impact of belimumab and rituximab on health-
related quality of life in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2019;71:811–21.

27 Alarcon GS, McGwin G Jr, Uribe A et al. Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course. Arthritis Rheum 2004;51:465–74.

28 Mina R, Klein-Gitelman MS, Nelson S et al. Effects of obesity on health-related quality of life in juvenile-onset systemic lupus erythematosus. Lupus 2015;24:191–7.

29 de Zwaan M, Petersen I, Kaerber M et al. Obesity and quality of life: a controlled study of normal-weight and obese individuals. Psychosomatics 2009;50:474–82.

30 Busutil R, Espallardo O, Torres A et al. The impact of obesity on health-related quality of life in Spain. Health Qual Life Outcomes 2017;15:197.

31 Hopman WM, Berger C, Joseph L et al. The association between body mass index and health-related quality of life: data from CaMos, a stratified population study. Qual Life Res 2007;16:1595–603.

32 Williams P, Goldberg D. A user’s guide to the General Health Questionnaire. Slough: NFER-Nelson, 1988.

33 Singer MA, Hopman WM, MacKenzie TA. Physical functioning and mental health in patients with chronic medical conditions. Qual Life Res 1999;8:687–91.

34 Burgos PI, Alarcon GS, McGwin G Jr et al. Disease activity and damage are not associated with increased levels of fatigue in systemic lupus erythematosus patients from a multiethnic cohort: LXVII. Arthritis Rheum 2009;61:1179–86.

35 Schneider M, Mosca M, Pego-Reigosa JM et al. Understanding remission in real-world lupus patients across five European countries. Lupus 2016;25:505–12.

36 Choi ST, KJ Park IH, Lee YW et al. Subscale analysis of quality of life in patients with systemic lupus erythematosus: association with depression, fatigue, disease activity and damage. Clin Exp Rheumatol 2012;30:665–72.

37 Parodis I, Sjowall C, Jonsen A et al. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. Autoimmun Rev 2017;16:343–51.

38 Thumboo J, Fong KY, Ng TP et al. Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J Rheumatol 1996;26:97–102.

39 Stoll T, Gordon C, Seifert B et al. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol 1997;24:1608–14.

40 Wang SL, Wu B, Zhu LA et al. Construct and criterion validity of the Euro Qol-5D in patients with systemic lupus erythematosus. PLoS One 2014;9:e98883.

41 Copay AG, Subach BR, Glassman SD, Polly DW Jr, Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 2007;7:541–6.

42 Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol 2003;56:395–407.